丹参酮ⅡA联合还原型谷胱甘肽治疗酒精性肝病临床观察

Clinical analysis of the function of Tanshinone ⅡA combined with reduced glutathione Injection in the treatment of alcoholic liver disease

目的:观察丹参酮IIA联合还原型谷胱甘肽治疗酒精性肝病(ALD)的临床疗效。方法:2010年2月至2011年11月收治酒精性肝病患者76例,丹参酮IIA联合还原型谷胱甘肽治疗37例作为观察组,常规治疗39例作为对照组,疗程均为6周,观察两组的疗效及不良反应。结果:治疗组与对照组总有效率分别为94.6%与82.1%,两组比较有差异性(P<0.05)。与对照组治疗后比较,肝功能改善更明显,差异有统计学意义(P<0.05)。治疗中均无明显不良反应。结论:丹参酮IIA联合还原型谷胱甘肽治疗ALD疗效满意,能够明显提高总有效率,安全性好,值得临床推广应用。

Objective： To the clinical effects of Tanshinone IIA combined with reduced glutathione in the treatment of alcoholic liver disease （ALD）. Methods： 76 patients with ALD In February 2010 tO November 2011 were divided into two groups： 37 cases of the treatment group was treated by tanshinone II A and reduced glutathione. 39 eases of the control group was treated by reduced gluta- thione, the period of treatment was six weeks. Then comparative analysis of the two groups and adverse reaction of curative effect. Re- sult ： The total efective rate of treatment group was 94. 6%, while control group was 82. 1%, there was significant difference （ P 〈 0. 05 ） . As compared with control group, treatment group had more obvious improvements on liver function after treatment, there were significant differences （ P 〈 0. 05 ）. There no side effect in both group. Conclusion： It＇ s satisfied to treat ALD with tanshinone IIA combined with reduced glutathione .